Tirzepatide 30mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Tirzepatide's dual agonism produces a pharmacology that neither parent class reproduces on its own, and the relative contribution of the GIP arm remains an active research question. The molecule is imbalanced by design, with greater potency at GIP receptors than at GLP-1 receptors, which is the feature most often probed in receptor-selectivity experiments. This 30mg vial is the largest tirzepatide presentation in the catalogue and is aimed at extended protocols and dose-response series where repeated small-vial reconstitution would introduce avoidable variance.
Frequently Bought Together
Tirzepatide 30mg
30mg
$99 USD
Bundle & Save
$199 USD
Save $9 USD
$264 USD
Save $24 USD
$309 USD
Save $49 USD
$409 USD
Save $84 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Mounjaro News: GLP-1 Drug May Lower Heart Attack Risk in Type 2 Diabetes
Recent reports suggest that Mounjaro, a GLP-1 receptor agonist for type 2 diabetes, may lower heart attack risk. This analysis explores the news, its potential implications for peptide research, and what it means for the industry.